Number of Reported Polio Cases in First Months of 2019 Up From 2018 - Contagionlive.com

Number of Reported Polio Cases in First Months of 2019 Up From 2018 - Contagionlive.com

Number of Reported Polio Cases in First Months of 2019 Up From 2018 - Contagionlive.com

Posted: 07 Jun 2019 12:00 AM PDT

The near eradication of poliomyelitis is one of the great public health achievements of the last century, but, in a new report detailing global progress made toward polio elimination, investigators say that the first months of 2019 have seen an uptick in cases of wild poliovirus compared with the same period in 2018.

More than 2.5 billion children have been vaccinated against polio since the start of the Global Polio Eradication Initiative in 1988, and since then the global incidence of polio cases has dropped by 99%. Today polio transmission continues in only 3 countries, and the new report published in the US Centers for Disease Control and Prevention's (CDC) Mortality and Morbidity Weekly Report details revised emergency action plans for polio vaccination in Afghanistan, Nigeria, and Pakistan, where polio continues to be endemic.

The new report details global cases of wild poliovirus (WPV) and circulating vaccine-derived poliovirus (cVDPV) and progress toward their eradication from January 1, 2017, to March 31, 2019. Since 2015 WPV type 2 (WPV2) has been declared eradicated, and no cases of WPV type 3 (WPV3) have been detected since 2012. There have also been no reported cases of WPV1 in the World Health Organization's (WHO) African Region in 30 months. For the first time since 2014, however, the number of WPV cases reported in Afghanistan and Pakistan rose, from 22 WPV1 cases in 2017 to 33 cases in 2018. In addition, from January through March 2019 there were 12 cases of WPV type 1 (WPV1) reported worldwide, 4 more than the 8 cases reported during the corresponding period in 2018.

"The increase in WPV1 cases tells us 2 things," study co-author Sharon A. Greene, PhD, told Contagion®. "First, our surveillance is sensitive enough to detect cases and to succeed in eradicating polio.  We must know where the virus is circulating.  Second, it tells us that children are not getting vaccinated. Inadequate immunization coverage, either through routine immunization programs or supplemental immunization activities must be strengthened to stop poliovirus circulation."
Although 88% of infants worldwide age 1 or older had received 3 doses of poliovirus vaccines in 2017, that rate of coverage was only 60% in Afghanistan, 40% in Nigeria, and 75% in Pakistan. In addition, in areas where oral poliovirus vaccine coverage is low, cases of cVDPV are more likely to occur, and from 2017 to 2019 there have been 210 cases of cVDPV reported in 8 countries.

Through supplemental immunization activities, about 3.5 billion doses of oral poliovirus vaccine and inactivated poliovirus vaccine have been allocated in 5 WHO regions, and Greene described the ongoing challenges in polio vaccination efforts. "The largest hurdle in the last mile to WPV eradication is missed children in the delivery of polio vaccines. In countries with reported WPV transmission, there are steep challenges to reaching every child and successfully vaccinating them, including, inaccessibility, mobile populations, weak routine immunization, gaps in supplemental immunization activities, and vaccine refusals."

Despite the recent uptick in cases, health officials say we're closer than ever to reaching target goals for polio. "CDC and the global public health community know that we are on threshold of polio eradication," said Greene. "Recent accomplishments include no detection of wild poliovirus in Nigeria for the past 33 months, and it is possible that the African Region may be certified WPV free in early 2020. We have the right tools for eradication. These strategies have succeeded in making much of the world polio-free. The final push requires us to double down on these efforts to ensure interruption of wild poliovirus."

To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.

Comments

Post a Comment

Popular posts from this blog

Roseola vs. measles rash: What is the difference? - Medical News Today

Image
Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
Read more

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T...
Read more

Coronavirus fake news echoes century-old polio fears - Newsroom

Image
Coronavirus fake news echoes century-old polio fears - Newsroom Coronavirus fake news echoes century-old polio fears - Newsroom Posted: 05 Feb 2020 08:32 AM PST FEBRUARY 6, 2020 Updated 15 hours ago Dr Heather Battles Dr Heather Battles is a lecturer in anthropology at the University of Auckland and researches infectious diseases and epidemics. Show more Ideasroom During the past month, in the confusion and uncertainty over the precise origin of the 2019 novel coronavirus outbreak, many alternate ideas or 'conspiracy theories' have sprung up and spread widely via social media including Twitter and Facebook. I have had a sense of déjà vu as many of these claims have parallels in how people responded to another 'emerging' epidemic disease a century ago: polio. The first example that struck me is the idea (spread by US fake news website Infowars and others) that the roll-out of 5G technology is to blame, wit...
Read more